TABLE 1.

Characteristics of MNC donors

DonorVaccineaSerum anti-PPS23F titerb (μg/ml)Serum isotypeNo. of Fabs/no. of clonescNo. of unique Fabsd
PrePost
001Conjugate0.9112.5IgG2/IgA0/8000
002Conjugate0.1716.9IgG2/IgA13/8003
004Conjugate1.4310.95IgG2/IgA0/5000
008Conjugate2.634.3IgG2/IgA11/40010
014Conjugate1.3415.6IgG2/IgA3/8003
018PPS11.922.07IgG2/IgA3/12001
023PPS11.075.8IgG2/IgA8/3003
025PPS0.310.98IgG2/IgA7/7006
027PPS5.624.32IgG2/IgA4/5004
  • a Conjugate vaccine (PPS types 1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F conjugated to CRM197) or PPS vaccine (23-valent PPS vaccine) was administered 7 days prior to the collection of MNC.

  • b Pre- and postvaccination PPS 23F-specific serum titers were determined for sera collected before and 30 days after vaccination.

  • c The number of PPS 23F-specific Fabs isolated divided by the number of individual colonies screened.

  • d The number of Fabs unique in L-chain sequence, H-chain sequence, or both.